Table 2 Clinicopathological and demographic characteristics of the study population classified by the participating center
From: Urine cell-based DNA methylation classifier for monitoring bladder cancer
Hospital Clinic Barcelona | Radboud University Medical Center, Nijmegen | Saint John Emergency Clinical Hospital Bucharest | MD Anderson Cancer Center Houston | Total | ||
|---|---|---|---|---|---|---|
Discovery phase | Bladder cancer urine samples | |||||
Stage | ||||||
Tis | 5 | – | 1 | 1 | 7 | |
Ta | 14 | 5 | 5 | 13 | 37 | |
T1 | 19 | 2 | 21 | – | 42 | |
> T2 | 9 | – | 16 | – | 25 | |
Grade | ||||||
LG | 20 | 2 | 17 | 8 | 47 | |
HG | 27 | 5 | 26 | 6 | 64 | |
Subtotal | 47 | 7 | 43 | 14 | 111 | |
Control urine samples | ||||||
BPH | 8 | 3 | – | – | 11 | |
Urolithiasis | 13 | – | – | – | 13 | |
Incontinence | 1 | 1 | – | – | 2 | |
Benign bladder disease | 4 | 5 | 1 | – | 10 | |
Urinary tract infection | 1 | 8 | 4 | – | 13 | |
Non-urological diseases | 6 | – | – | 2 | 8 | |
Subtotal | 33 | 17 | 5 | 2 | 57 | |
Validation phase | R-PFBC URINE SAMPLES | |||||
Stage | ||||||
Tis | 2 | 1 | 8 | 2 | 13 | |
Ta | 13 | 15 | 47 | 6 | 81 | |
T1 | 4 | 2 | 55 | 18 | 79 | |
Grade | ||||||
LG | 14 | 8 | 74 | – | 96 | |
HG | 5 | 10 | 36 | 26 | 77 | |
Subtotal | 19 | 18 | 110 | 26 | 173 | |
NR-PFBC urine samples | ||||||
Stage previous TURBT | ||||||
Tis | 5 | 6 | 6 | 4 | 21 | |
Ta | 32 | 56 | 36 | 26 | 150 | |
Ta + CIS | 1 | – | – | 2 | 3 | |
T1 | 36 | 16 | 25 | 19 | 96 | |
T1 + CIS | 5 | – | – | 3 | 8 | |
T2 | 3 | – | – | – | 3 | |
Tx | 4 | – | – | – | 4 | |
Grade previous TURBT | ||||||
LG | 34 | 35 | 38 | 19 | 126 | |
HG | 52 | 43 | 29 | 35 | 159 | |
Subtotal | 86 | 78 | 67 | 54 | 285 | |
TOTAL | 185 | 120 | 225 | 96 | 626 | |